Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase

Cell Cycle

Volumn 11, Issue 18, 2012, Pages 3492-3503

  Karakaya, Kadin ^a,b   Herbst, Friederike ^a   Ball, Claudia ^a   Glimm, Hanno ^a   Krämer, Alwin ^a,b   Löffler, Harald ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Centrosome amplification; Chromosomal instability; Cytokinesis; EVI1; Mitosis

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; TRANCRIPTION FACTOR EVI1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHROMOSOME NUMBER; CONTROLLED STUDY; CYTOKINESIS; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC PARAMETERS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PHENOTYPE; POLYPLOIDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNUMERARY CENTROSOME; TETRAPLOIDIZATION; TETRAPLOIDY;

EID: 84866761541     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21801     Document Type: Article

References (54)

1. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396:643-9; PMID:9872311; http://dx.doi.org/10.1038/25292.
2. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004; 432:338-41; PMID:15549096; http://dx.doi.org/10.1038/nature03099.
3. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791-7; PMID:18695255; http://dx.doi.org/10.1200/JCO.2008.16. 0259.
4. Heilig CE, Löffler H, Mahlknecht U, Janssen JW, Ho AD, Jauch A, et al. Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J Cell Mol Med 2010; 14:895-902; PMID:19754665; http://dx.doi.org/10.1111/j.1582-4934. 2009.00905.x.
5. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010; 116:2224-8; PMID:20562328; http://dx.doi.org/10.1182/blood-2010-02-270330.
6. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988; 54:831-40; PMID:2842066; http://dx.doi.org/10.1016/S0092-8674(88)91175-0.
7. Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang JM, et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer 1996; 74:1518-25; PMID:8932329; http://dx.doi.org/10.1038/bjc.1996.583.
8. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006; 66:8404-12; PMID:16951150; http://dx.doi.org/10.1158/0008-5472. CAN-06-0683.
9. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poelvan de Luytgaarde S, Hack R, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101:837-45; PMID:12393383; http://dx.doi.org/10. 1182/blood-2002-05-1459.
10. Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84:1243-8; PMID:8049440.
11. Dreyfus F, Bouscary D, Melle J, Ribrag V, Guesnu M, Varet B. Expression of the Evi-1 gene in myelodysplastic syndromes. Leukemia 1995; 9:203-5; PMID:7845018.
12. Ohyashiki JH, Ohyashiki K, Shimamoto T, Kawakubo K, Fujimura T, Nakazawa S, et al. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression. Blood 1995; 85:3713-8; PMID:7780155.
13. Ogawa S, Kurokawa M, Tanaka T, Tanaka K, Hangaishi A, Mitani K, et al. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia 1996; 10:788-94; PMID:8656673.
14. Langabeer SE, Rogers JR, Harrison G, Wheatley K, Walker H, Bain BJ, et al.; MRC Adult Leukaemia Working Party. EVI1 expression in acute myeloid leukaemia. Br J Haematol 2001; 112:208-11; PMID:11167805; http://dx.doi.org/10. 1046/j.1365-2141.2001.02569.x.
15. Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt HH, et al. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer 2003; 36:80-9; PMID:12461752; http://dx.doi.org/10.1002/gcc.10144.
16. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198-204; PMID:20098431; http://dx.doi.org/10.1038/nm.2088.
17. Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28:2101-7; PMID:20308656; http://dx.doi.org/ 10.1200/JCO.2009.26.0646.
18. Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, et al. Clinical, molecular, and prognostic significance of WHO type inv(3) (q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28:3890-8; PMID:20660833; http://dx.doi.org/10.1200/JCO.2010.29.2771.
19. Shi G, Weh HJ, Dührsen U, Zeller W, Hossfeld DK. Chromosomal abnormality inv(3)(q21q26) associated with multilineage hematopoietic progenitor cells in hematopoietic malignancies. Cancer Genet Cytogenet 1997; 96:58-63; PMID:9209472; http://dx.doi.org/10.1016/S0165-4608(96)00293-2.
20. Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. Blood 1985; 66:1362-70; PMID:4063525.
21. Grigg AP, Gascoyne RD, Phillips GL, Horsman DE. Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. Br J Haematol 1993; 83:158-65; PMID:8435325; http://dx.doi.org/10.1111/j.1365-2141.1993.tb04647.x.
22. Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994; 8:1318-26; PMID:8057667.
23. Horsman DE, Gascoyne RD, Barnett MJ. Acute leukemia with structural rearrangements of chromosome 3. Leuk Lymphoma 1995; 16:369-77; PMID:7787746; http://dx.doi.org/10.3109/10428199509054422.
24. Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995; 91:490-501; PMID:8547101; http://dx.doi.org/10.1111/j.1365-2141. 1995.tb05329.x.
25. Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, et al. Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features. Hematol J 2002; 3:21-31; PMID:11960392; http://dx.doi.org/10.1038/sj.thj.6200143.
26. Stevens-Kroef M, Poppe B, van Zelderen-Bhola S, van den Berg E, van der Blij-Philipsen M, Geurts van Kessel A, et al. Translocation t(2;3)(p15-23;q26- 27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. Leukemia 2004; 18:1108-14; PMID:15085164; http://dx.doi.org/10.1038/sj.leu.2403346.
27. Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer 2006; 45:349-56; PMID:16342172; http://dx.doi.org/10.1002/gcc.20295.
28. Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 2007; 396:346-57; PMID:17507183; http://dx.doi.org/10.1016/j.gene.2007.04.012.
29. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, et al. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 2000; 19:2958-68; PMID:10856240; http://dx.doi.org/10.1093/emboj/19.12.2958.
30. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2005; 24:1976-87; PMID:15889140; http://dx.doi.org/10.1038/sj.emboj.7600679.
31. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/ AKT. Oncogene 2006; 25:3565-75. PMID:16462766; http://dx.doi.org/10.1038/ sj.onc.1209403
32. Konrad TA, Karger A, Hackl H, Schwarzinger I, Herbacek I, Wieser R. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. J Leukoc Biol 2009; 86:813-22; PMID:19605700; http://dx.doi.org/10.1189/jlb.0109042.
33. Kilbey A, Alzuherri H, McColl J, Calés C, Frampton J, Bartholomew C. The Evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity. Br J Haematol 2005; 130:902-11. PMID:16156860; http://dx.doi.org/10.1111/j.1365-2141.2005.05709.x
34. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009; 460:278-82; PMID:19506557; http://dx.doi.org/10.1038/nature08136.
35. Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A, et al. Centrosome amplification can initiate tumorigenesis in flies. Cell 2008; 133:1032-42; PMID:18555779; http://dx.doi.org/10.1016/j.cell.2008.05.039.
36. Krämer A. Centrosome aberrations - hen or egg in cancer initiation and progression? Leukemia 2005; 19:1142-4; PMID:15858612; http://dx.doi.org/10. 1038/sj.leu.2403780.
37. Boutros R, Lobjois V, Ducommun B. CDC25B involvement in the centrosome duplication cycle and in microtubule nucleation. Cancer Res 2007; 67:11557-64; PMID:18089784; http://dx.doi.org/10.1158/0008-5472.CAN-07-2415.
38. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA. The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol 2005; 7:1140-6; PMID:16244668; http://dx.doi.org/10.1038/ncb1320.
39. Leidel S, Delattre M, Cerutti L, Baumer K, Gönczy P. SAS-6 defines a protein family required for centrosome duplication in C. elegans and in human cells. Nat Cell Biol 2005; 7:115-25; PMID:15665853; http://dx.doi.org/10.1038/ ncb1220.
40. Löffler H, Fechter A, Matuszewska M, Saffrich R, Mistrik M, Marhold J, et al. Cep63 recruits Cdk1 to the centrosome: implications for regulation of mitotic entry, centrosome amplification, and genome maintenance. Cancer Res 2011; 71:2129-39; PMID:21406398; http://dx.doi.org/10.1158/0008-5472.CAN-10- 2684.
41. Stevens NR, Roque H, Raff JW. DSas-6 and Ana2 coassemble into tubules to promote centriole duplication and engagement. Dev Cell 2010; 19:913-9; PMID:21145506; http://dx.doi.org/10.1016/j.devcel.2010.11.010.
42. Löffler H, Bochtler T, Fritz B, Tews B, Ho AD, Lukas J, et al. DNA damage-induced accumulation of centrosomal Chk1 contributes to its checkpoint function. Cell Cycle 2007; 6:2541-8; PMID:17726372; http://dx.doi.org/10.4161/ cc.6.20.4810.
43. Takada S, Kelkar A, Theurkauf WE. Drosophila checkpoint kinase 2 couples centrosome function and spindle assembly to genomic integrity. Cell 2003; 113:87-99; PMID:12679037; http://dx.doi.org/10.1016/S0092-8674(03)00202-2.
44. Bourke E, Dodson H, Merdes A, Cuffe L, Zachos G, Walker M, et al. DNA damage induces Chk1- dependent centrosome amplification. EMBO Rep 2007; 8:603-9; PMID:17468739; http://dx.doi.org/10.1038/sj.embor.7400962.
45. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 2002; 21:483-92; PMID:11847097; http://dx.doi.org/10.1093/emboj/21.4.483.
46. Guarguaglini G, Duncan PI, Stierhof YD, Holmström T, Duensing S, Nigg EA. The forkhead-associated domain protein Cep170 interacts with Polo-like kinase 1 and serves as a marker for mature centrioles. Mol Biol Cell 2005; 16:1095-107; PMID:15616186; http://dx.doi.org/10.1091/mbc.E04-10-0939.
47. Löffler H, Fechter A, Liu FY, Poppelreuther S, Krämer A. DNA damage-induced centrosome amplification occurs via excessive formation of centriolar satellites. Oncogene 2012; PMID:22824794; http://dx.doi.org/10.1038/ onc.2012.310.
48. Vulprecht J, David A, Tibelius A, Castiel A, Konotop G, Liu F, et al. STIL is required for centriole duplication in human cells. J Cell Sci 2012; 125:1353-62; PMID:22349705; http://dx.doi.org/10.1242/jcs.104109.
49. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23:7212-20; PMID:16192605; http://dx.doi.org/10.1200/JCO.2005.07.501.
50. Kilbey A, Stephens V, Bartholomew C. Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts. Cell Growth Differ 1999; 10:601-10. (Pubitemid 29455724)
51. Storchova Z, Kuffer C. The consequences of tetraploidy and aneuploidy. J Cell Sci 2008; 121:3859-66; PMID:19020304; http://dx.doi.org/10.1242/jcs.039537.
52. Shackney SE, Smith CA, Miller BW, Burholt DR, Murtha K, Giles HR, et al. Model for the genetic evolution of human solid tumors. Cancer Res 1989; 49:3344-54; PMID:2720687.
53. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25:217-22; PMID:10835641; http://dx.doi.org/10.1038/ 76095.
54. Lukas J, Bartek J. Immunoprecipitation of proteins under nondenaturing conditions. In: Celis JE, ed. Cell Biology: A Laboratory Handbook. San Diego: Academic Press, 1998:489-94.